Researcher:
Şeref, Ceren

Profile Picture
ORCID

Job Title

PhD Student

First Name

Ceren

Last Name

Şeref

Name

Name Variants

Şeref, Ceren

Email Address

Birth Date

Filters

2016 - 201932020 - 20221

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.04776e0f-3198-4c87-a1dc-f6297e122738

Search Results

Now showing 1 - 4 of 4
  • Placeholder
    PublicationMetadata only
    Cytokine response in crimean-congo hemorrhagic fever virus infection
    (Wiley, 2017) Eren, Şebnem; Çelikbaş, Aysel; Baykam, Nurcan; Dokuzoğuz, Başak; N/A; N/A; Department of Industrial Engineering; N/A; Ergönül, Önder; Şeref, Ceren; Gönen, Mehmet; Can, Füsun; Faculty Member; PhD Student; Faculty Member; Faculty Member; Department of Industrial Engineering; School of Medicine; Graduate School of Health Sciences; College of Engineering; School of Medicine; Koç University Hospital; 110398; N/A; 237468; 103165
    We described the predictive role of cytokines in fatality of Crimean Congo Hemorrhagic Fever Virus (CCHFV) infection by using daily clinical sera samples. Consequent serum samples of the selected patients in different severity groups and healthy controls were examined by using human cytokine 17-plex assay. We included 12 (23%) mild, 30 (58%) moderate, 10 (19%) severe patients, and 10 healthy volunteers. The mean age of the patients was 52 (sd 15), 52% were female. Forty-six patients (88%) received ribavirin. During disease course, the median levels of IL-6, IL-8, IL-10, IL-10/12, IFN-gamma, MCP-1, and MIP-1b were found to be significantly higher among CCHF patients than the healthy controls. Within the first 5 days after onset of disease, among the fatal cases, the median levels of IL-6 and IL-8 were found to be significantly higher than the survived ones (Fig. 3), and MCP-1 was elevated among fatal cases, but statistical significance was not detected. In receiver operating characteristic (ROC) analysis, IL-8 (92%), IL-6 (92%), MCP-1 (79%) were found to be the most significant cytokines in predicting the fatality rates in the early period of the disease (5 days). IL-6 and IL-8 can predict the poor outcome, within the first 5 days of disease course. Elevated IL-6 and IL-8 levels within first 5 days could be used as prognostic markers.
  • Placeholder
    PublicationMetadata only
    Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations
    (Wiley, 2022) Sağlıcan, Yeşim; İnce, Ümit; Kılıc, Mert; Vural, Metin; Coşkun, Bilgen; N/A; N/A; N/A; N/A; N/A; Şeref, Ceren; Acar, Ömer; Saraç, Hilal; Esen, Tarık; Lack, Nathan Alan; PhD Student; Faculty Member; PhD Student; Faculty Member; Faculty Member; Graduate School of Health Sciences; School of Medicine; Graduate School of Sciences and Engineering; School of Medicine; School of Medicine; N/A; 237530; N/A; 50536; 120842
    Background: The detection rate of clinically significant prostate cancer has improved with the use of multiparametric magnetic resonance imaging (mpMRI). Yet, even with MRI-guided biopsy 15%-35% of high-risk lesions (Prostate Imaging-Reporting and Data System [PI-RADS] 4 and 5) are histologically benign. It is unclear if these false positives are due to diagnostic/sampling errors or pathophysiological alterations. To better understand this, we tested histologically benign PI-RAD 4 and 5 lesions for common malignant epigenetic alterations. Materials and Methods: MRI-guided in-bore biopsy samples were collected from 45 patients with PI-RADS 4 (n = 31) or 5 (n = 14) lesions. Patients had a median clinical follow-up of 3.8 years. High-risk mpMRI patients were grouped based on their histology into biopsy positive for tumor (BPT; n = 28) or biopsy negative for tumor (BNT; n = 17). From these biopsy samples, DNA methylation of well-known tumor suppressor genes (APC, GSTP1, and RAR beta 2) was quantified. Results: Similar to previous work we observed high rates of promoter methylation at GSTP1 (92.7%), RAR beta 2 (57.3%), and APC (37.8%) in malignant BPT samples but no methylation in benign TURP chips. Interestingly, similar to the malignant samples the BNT biopsies also had increased methylation at the promoter of GSTP1 (78.8%) and RAR beta 2 (34.6%). However, despite these epigenetic alterations none of these BNT patients developed prostate cancer, and those who underwent repeat mpMRI (n = 8) demonstrated either radiological regression or stability. Conclusions: Histologically benign PI-RADS 4 and 5 lesions harbor prostate cancer-associated epigenetic alterations.
  • Placeholder
    PublicationMetadata only
    The clinical impact of ST131 H30-Rx subclone in urinary tract infections due to multidrug-resistant Escherichia coli
    (Elsevier, 2016) Kurt-Azap, Özlem; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; Can, Füsun; İspir, Pelin; Nurtop, Elif; Şeref, Ceren; Loçlar, İlayda; Aktaş, Özge Nur; Orhan, Yelda Ceren; Ergönül, Önder; Faculty Member; Master Student; Master Student; PhD Student; Undergraduate Student; Undergraduate Student; Undergraduate Student; Faculty Member; School of Medicine; Graduate School of Health Sciences; Graduate School of Health Sciences; Graduate School of Health Sciences; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 103165; N/A; N/A; N/A; N/A; N/A; N/A; 110398
    In this study, risk factors for ST131 H30 and H30-Rx subclones among urinary tract infections (UTIs) caused by multidrug-resistant (MDR) Escherichia coli were described. Urine samples were collected from consecutive outpatients registered to the outpatient clinics of Bas, kent University Hospital (Ankara, Turkey) with complaints of acute cystitis in 2011. A total of 107 MDR E. coli isolates were included in the study. of the 107 isolates studied, 26 (24.3%) were typed as ST131 clone. Extended-spectrum beta-lactamase (ESBL)-producers accounted for 59 (55.1%) of the 107 isolates. Among the 59 ESBL-positive isolates, 18 (31%) were found to belong to the ST131 clone. of the 18 ESBL-positive ST131 isolates, 17 (94%) were defined as H30 subclone, among which 16 (94%) represented the H30-Rx subclone. Among the 48 ESBL-negative isolates, 8 (17%) ST131 isolates were detected, 7 (88%) of which belonged to H30 subclone; 5 (71%) of the H30 subclone isolates were classified under H30-Rx subclone. In multivariate analysis, hospitalisation within last year was the only host risk factor associated with MDR E. coli ST131 H30-Rx subclone UTI (OR = 3.5, 95% CI 1.04-12.17; P = 0.042). CTX-M-15 production was found to be highly associated with the presence of ST131 H30-Rx subclone (OR = 4.8, 95% CI 1.54-15.32; P = 0.007). In conclusion, urinary MDR E. coli ST131 H30-Rx subclone was found to be important in the dissemination of MDR UTIs in the community. Approximately 20% of the MDR isolates were H30-Rx subclone. Infection with this subclone was found to be healthcare-associated. (C) 2015 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.
  • Placeholder
    PublicationMetadata only
    Molecular epidemiology of bloodstream-associated Escherichia coli ST131 H30-Rx subclone infection in a region with high quinolone resistance
    (Microbiology Society, 2016) Kurt-Azap, Özlem; N/A; N/A; N/A; N/A; N/A; Can, Füsun; Nurtop, Elif; İspir, Pelin; Şeref, Ceren; Ergönül, Önder; Faculty Member; Master Student; Master Student; PhD Student; Faculty Member; School of Medicine; Graduate School of Health Sciences; Graduate School of Health Sciences; Graduate School of Health Sciences; School of Medicine; 103165; N/A; N/A; N/A; 110398
    Bloodstream infections caused by Escherichia coli ST131 and ST131 H30-Rx subclones have emerged worldwide. This study was carried out to evaluate the prevalence of the ST131-Rx subclone and characterize the virulence properties of the Rx isolates among the bloodstream E. coli isolates. A total of 297 non-duplicated E. coli bloodstream isolates were studied. Antibiotic susceptibilities were tested using the disc diffusion method. PCR amplification and sequencing was used to identify ST131 and H30-Rx, the virulence gene, the beta-lactamase and virotype. Quinolone resistance among bacteraemic E. coli strains was 51 %, and it was 98% among E. coli ST131 isolates. The ST131 isolates accounted for 16% (49) of all isolates and all ST131 isolates belonged to the extraintestinal pathogenic E. coli. The proportion of H30 subclone among the ST131 isolates was 98%, and 75 % of H30 isolates belonged to the H30-Rx subclone. The prevalence of ST131 increased from 13 to 23 % in 4 years; however, there was a decrease in the ratio of H30-Rx infections. CTX-M-15 was detected in 85% of ST131 and all of the H30-Rx isolates. The virulence genes associated with adhesion, cell protection, iron uptake and toxins (papA, iha, kpsMTII, iut and sat) were more common in ST131 than in non-ST131 isolates. Most of the ST131 and H30-Rx isolates were of the C virotype. All papA-positive isolates were in virotype C. The E. coli ST131 clone has increased rapidly among bloodstream isolates. However, a decrease in the proportion of the H30-Rx subclone in the quinolone-resistant population suggests the possibility of dissemination of other virulent and quinolone-resistant subclones in hospital settings.